

NCT ID	NCT02668770
Title	Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase	Phase 1
Date Added	2016-01-29
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Ipilimumab, MGN1703
Tags	MSS/ MMRp
NCT ID	NCT02617277
Title	Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Phase	Phase 1
Date Added	2015-11-30
Location	Colorado, United States Florida, United States Tennessee, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	AZD1775, MEDI4736
Tags	MSS/ MMRp
NCT ID	NCT02608385
Title	Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Phase	Phase 1
Date Added	2015-11-18
Location	Illinois, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSS/ MMRp
NCT ID	VAPER
Title	A study looking at using a vaccine and chemotherapy to treat advanced cancer
Phase	Phase 1
Date Added	2015-11-17
Location	
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Celecoxib, Cyclophosphamide, imiquimod, vaccine
Tags	MSS/ MMRp
NCT ID	NCT02600949
Title	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Phase	Phase 1
Date Added	2015-11-09

Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Enrolling by invitation
Drugs	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02537418
Title	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Phase	Phase 1
Date Added	2015-09-01
Location	Canada
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	durvalumab, Tremelimumab, Imfinzi
Tags	MSS/ MMRp
NCT ID	NCT02499328
Title	Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Phase	Phase 1, Phase 2
Date Added	2015-07-16
Location	Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Completed
Drugs	AZD5069, AZD9150, MEDI4736, tremelimumab (treme)
Tags	MSS/ MMRp
NCT ID	NCT02484404
Title	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Phase	Phase 1, Phase 2
Date Added	2015-06-29
Location	Maryland, United States
Prior IO Allowed	Yes

CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT02465060
Title	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase	Phase 2
Date Added	2015-06-08
Location	Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico
Prior IO Allowed	Yes

CRC-directed	Yes
Status	Active, not recruiting
Drugs	Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT02453620
Title	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase	Phase 1
Date Added	2015-05-25
Location	California, United States Connecticut, United States Maryland, United States Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSS/ MMRp